Static Marker
Whole genome sequencing companies, BRACA1 text, etc.
Indicates predisposition to develop cancer, not certainty
Eg. BRACA1 test, Whole genome sequencing companies
Gene Mapping: Cannot indicate cancer present or imminent cancer
Dynamic & Causative Marker
Tissue Biopsies
TZAR patented blood test
RNA Expression detected typically throgh biopsies
Mutations can indicate stage of cancer Define “Early Detection” as tumour is absent - PRE-STAGE 1
TZAR can indicate tissue RNA readings from the blood using its patented algorithm
Resultant/Surrogate Marker
Liquid Biopsies
Methylation based approach etc.
CTC/CtDNA detection will indicate cancer present
Issue of “FALSE NEGATIVES” – CTC not present does not indicate cancer absent
ASCO 2019 had presentations where Liquid Biopsy leaders indicated 28% successful detection results - WEAK DETECTION
DEFINE “Early Detection as Tumour Present” – STAGE 1+
Tzar labs has pioneered a proprietary technology which can detect organ level transcriptome analysis and somatic mutations directly from the blood sample.
Of the 311 immunomolecular marker genes that we have been monitoring, we have identified 6-20 genes that serve as molecular indicators for cancerous condition
Using the hybrid expression of an array of these genes, we have developed an algorithm which can predictively indicate the distant occurrence of cancer in healthy individuals or relapse (in case of treated individuals)
The algorithm can also be extended to speculate the various stages of cancer (I, II, III, IV) based on the genetic mutation
The test requires an individual's peripheral blood sample
We have filed a US Patent for our diagnostic technology
1. Whether cancer is absent / present / imminent
2. Secondly, The level of the HrC lets us know the stage of cancer.
3. Thirdly, organ level gene mutations together with HrC lets us know the site of the cancer.
